BidaskClub upgraded shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Tuesday, July 25th.
A number of other analysts have also recently commented on RARE. Jefferies Group LLC cut shares of Ultragenyx Pharmaceutical from a buy rating to a hold rating and cut their target price for the stock from $109.00 to $66.00 in a research note on Thursday, April 6th. HC Wainwright cut shares of Ultragenyx Pharmaceutical from a buy rating to a neutral rating and cut their target price for the stock from $88.00 to $72.00 in a research note on Wednesday, April 19th. Wedbush cut shares of Ultragenyx Pharmaceutical from an outperform rating to a neutral rating and cut their target price for the stock from $80.00 to $75.00 in a research note on Wednesday, April 19th. Canaccord Genuity reissued a buy rating and set a $100.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 19th. Finally, SunTrust Banks, Inc. boosted their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $105.00 and gave the stock a buy rating in a research note on Wednesday, April 19th. One analyst has rated the stock with a sell rating, nine have given a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $84.87.
Ultragenyx Pharmaceutical (NASDAQ RARE) traded up 0.11% on Tuesday, hitting $64.14. 203,682 shares of the company’s stock traded hands. The stock has a 50-day moving average of $65.29 and a 200-day moving average of $67.43. Ultragenyx Pharmaceutical has a one year low of $51.67 and a one year high of $91.35. The stock’s market cap is $2.72 billion.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.73) by $0.01. During the same quarter in the previous year, the firm posted ($1.46) EPS. On average, equities analysts forecast that Ultragenyx Pharmaceutical will post ($7.23) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/08/08/ultragenyx-pharmaceutical-inc-rare-upgraded-to-buy-by-bidaskclub-updated.html.
In other Ultragenyx Pharmaceutical news, VP Theodore Alan Huizenga sold 480 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $57.46, for a total value of $27,580.80. Following the transaction, the vice president now directly owns 9,366 shares in the company, valued at approximately $538,170.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 9.20% of the company’s stock.
Several large investors have recently added to or reduced their stakes in RARE. Fortaleza Asset Management Inc. increased its stake in Ultragenyx Pharmaceutical by 148.5% in the first quarter. Fortaleza Asset Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 980 shares during the period. Sei Investments Co. bought a new stake in Ultragenyx Pharmaceutical during the second quarter worth about $125,000. Pacer Advisors Inc. increased its stake in Ultragenyx Pharmaceutical by 22.6% in the first quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 560 shares during the period. Strs Ohio increased its stake in Ultragenyx Pharmaceutical by 10.7% in the first quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 300 shares during the period. Finally, Tocqueville Asset Management L.P. increased its stake in Ultragenyx Pharmaceutical by 8.0% in the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares during the period. 95.40% of the stock is currently owned by institutional investors and hedge funds.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
